Advanced Heart Failure Clinical Trial
— US-IJVD-CHFOfficial title:
Ultrasound-assessed Internal Jugular Vein Distensibility to Predict Right Atrial Pressure and Other Hemodynamic Parameters in Patients With Advanced Chronic Heart Failure
Verified date | March 2022 |
Source | Niguarda Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Prospective validation of the ultrasound-assessed internal jugular vein distensibility (JVD) ratio to identify patients with systolic chronic heart failure and right atrial pressure (RAP) of 7 or less mmHg measured by the right heart catheterization. In a calibration cohort, a threshold ratio will be identified, above which the RAP is normal with the highest accuracy. This diagnostic tool with a defined threshold of the JVD ratio will be assessed in a second prospective validation cohort.
Status | Active, not recruiting |
Enrollment | 200 |
Est. completion date | December 31, 2022 |
Est. primary completion date | February 27, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - All patients with systolic chronic heart failure defined by a left ventricular ejection fraction (LVEF) <50% on echocardiogram that, undergo elective RHC in the heart transplant/left ventricular assist device work-up. - In case of occlusion of the left internal jugular vein (IJV), the RHC is performed from to contralateral IJV, and US-assessed JVD ratio will be measured on the right IJV. Exclusion Criteria: - Patients supported by a left ventricular assist device. - Patients with acute heart failure that undergo RHC as an urgent procedure in hemodynamically unstable patients. - Patients unable/unwilling to sign a written informed consent. - Patients in which an RHC is not feasible from an internal jugular vein. |
Country | Name | City | State |
---|---|---|---|
Italy | De Gasperis Cardio Center, Niguarda Hospital | Milano | Lombardy |
Lead Sponsor | Collaborator |
---|---|
Niguarda Hospital |
Italy,
Caldentey G, Khairy P, Roy D, Leduc H, Talajic M, Racine N, White M, O'Meara E, Guertin MC, Rouleau JL, Ducharme A. Prognostic value of the physical examination in patients with heart failure and atrial fibrillation: insights from the AF-CHF trial (atrial fibrillation and chronic heart failure). JACC Heart Fail. 2014 Feb;2(1):15-23. doi: 10.1016/j.jchf.2013.10.004. Epub 2014 Jan 8. — View Citation
McGee SR. Physical examination of venous pressure: a critical review. Am Heart J. 1998 Jul;136(1):10-8. Review. — View Citation
Pellicori P, Kallvikbacka-Bennett A, Dierckx R, Zhang J, Putzu P, Cuthbert J, Boyalla V, Shoaib A, Clark AL, Cleland JG. Prognostic significance of ultrasound-assessed jugular vein distensibility in heart failure. Heart. 2015 Jul;101(14):1149-58. doi: 10.1136/heartjnl-2015-307558. Epub 2015 May 25. — View Citation
Simon MA, Kliner DE, Girod JP, Moguillansky D, Villanueva FS, Pacella JJ. Detection of elevated right atrial pressure using a simple bedside ultrasound measure. Am Heart J. 2010 Mar;159(3):421-7. doi: 10.1016/j.ahj.2010.01.004. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Relationship between JVD ratio and other hemodynamic parameters obtained by RHC | The hemodynamic parameters will include pulmonary artery pressures and pulmonary capillary wedge pressure | From July 2017 to June 2019 | |
Primary | Identification of patients with normal RAP (=<7 mmHg) with US-IJVD based on the JVD ratio obtained from the calibration cohort. | Positive predictive value (PPV) of the JVD ratio to identify patients with normal (RAP=<7 mmHg) measured by RHC in the validation group. In particular a higher JVD ratio indicated lower RAP. | From July 2017 to June 2019 | |
Secondary | Clinical major cardiac events among patients included in the calibration group divided on the basis of the JVD ratio | Clinical events include cardiac death, unknown death, cardiac hospitalization, urgent heart transplant, left ventricular assist device implantation. In particular it is expected that patients with JVD ratio above the identified threshold in the calibration group have a better outcome. | From July 2017 to June 2019 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Suspended |
NCT02962973 -
European Clinical Evaluation of the Carmat Total Artificial Heart
|
N/A | |
Recruiting |
NCT04915924 -
Post Market Surveillance of the HeartMate 3 Left Ventricular Assist System in Korea
|
N/A | |
Completed |
NCT01626404 -
Screening for Advanced Heart Failure Treatment (SEE-HF)
|
||
Withdrawn |
NCT00572286 -
Non-invasive Evaluation of Heart Transplant Rejection- Pilot Study
|
N/A | |
Completed |
NCT00690157 -
Registry of Patients Referred for Heart Transplantation
|
N/A | |
Enrolling by invitation |
NCT00988806 -
Long-Term Intermittent Administration of Levosimendan in Patients With Advanced Heart Failure
|
Phase 4 | |
Recruiting |
NCT05284955 -
Screening for Advanced Heart Failure IN Stable outPatientS - The SAINTS Study (SAINTS B)
|
Phase 4 | |
Completed |
NCT01643551 -
Neuron Specific Enolase in Ventricular Assist Device Recipients
|
N/A | |
Terminated |
NCT04703855 -
Hong Kong and Taiwan HM3 PMS
|
N/A | |
Suspended |
NCT04851236 -
Pilot Study of Massage Therapy to Improve Self Efficacy in Patients With Left-ventricular Device
|
Early Phase 1 | |
Recruiting |
NCT03526627 -
Advanced Care Management in Patients With Advanced Heart Failure
|
||
Recruiting |
NCT06228209 -
Tier - Palliative Care For Patients With Advanced Heart Failure or Cancer
|
N/A | |
Active, not recruiting |
NCT06259045 -
Cardiac Cachexia in Advanced Heart Failure
|
||
Recruiting |
NCT05271214 -
Conservative Management of Left Ventricular Assist Device Candidates
|
||
Recruiting |
NCT04475393 -
Carmat Total Artificial Heart as a Bridge to Transplant in Patients With Advanced Heart Failure
|
N/A | |
Recruiting |
NCT03911349 -
Wrist Worn Blood Pressure Measurement
|
N/A | |
Recruiting |
NCT03919136 -
Wrist Worn Blood Pressure Measurement
|
||
Completed |
NCT01210573 -
Prospective Observation of Exercise Parameters in Advanced Heart Failure
|
N/A | |
Recruiting |
NCT04423562 -
PROgnostic Value of Exercise Capacity Measured as Peak Oxygen Uptake (pVO2) in Recipients of Left Ventricular Assist Devices
|